A Pilot Study of Omalizumab to Treat Severe Allergic Asthma in South Indian Population

Background: Asthma is a respiratory disease that affects your lungs. In asthma, airways of the lungs constrict due to swelling and accumulation mucus. Newer remedies known as targeted therapies have evolved result advancements in medical research, greatly relieving these patients. The biologics used severe allergic asthma Omalizumab.
 Purpose: Demonstrating clinical efficacy Omalizumab by reducing exacerbation rates increasing quality life.
 Methods: A single-arm prospective pilot study omalizumab was conducted tertiary care hospital for duration one year with help Quality Life Questionnaire (AQLQ).
 Results discussions: On an initial dose 150 mg 2 vials subcutaneously every month 6 months, among our population, 45% patients had their symptoms improve more than they prior medications. show patient's overall score has improved nearly 50%. This shows improves life asthmatic patients.
 Conclusion: Patients treated conditions life, it can prevent exacerbations controlling severity condition.
 Keywords: AQLQ, Allergic Exacerbation, IgE, Omalizumab.